drugset / Trial / NCT00232206
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
Phase 2
Terminated
40 enrolled
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute · collabSanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC). Secondary objectives of this study include assessment of radiographic response rate by computed tomography (CT) scanning, overall survival, time to progression, rate of complete surgical removal, and adverse reactions. In addition, this study will test whether positron emission tomography (PET) imaging can predict a tumor response. Patients who have a response to chemotherapy may receive 2 additional cycles after recovering from surgery.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-04
- Completion
- 2007-11
Outcome
Outcome not reported
Stopped (Enrollment): “study terminated due to slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |